Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

Abstract: A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4 is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A are each independently hydrogen, halogen, alkyl, or the like; R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R1 is or the like,

Abstract: The present application is concerned with methods for increasing the bioavailability and/or activity of agents and in particular allows selective targeting of an agent to, or via, the liver or allows the liver to be bypassed. By selecting which of saturated fatty acids (SFA), short chain fatty acids (SCFA), medium chain fatty acids (MCFA), polyunsaturated fatty acids (PUFA), monounsaturated fatty acids (MUFAs) and long chain fatty acids (LCFA) are present in a composition and which predominates it is possible to substantially boost bioavailability and also to selectively target whether an agent is delivered to, or via, the liver or alternatively bypasses the liver. The approach is a versatile platform technology which may be applied to agents in general helping achieve better and more efficient delivery. In one preferred embodiment particular carotenoids are employed to further influence whether delivery is to, or via, the liver, or bypasses the liver.

Abstract: Provided herein are methods and compositions related to treating and/or preventing cystic fibrosis in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.

Abstract: The present invention relates to the novel use of read-through compounds for use in the treatment and/or prevention of Autism Spectrum Disorder.

Abstract: Compositions can comprise the flavanol metabolite 3?-O-glucuronide epicatechin (3GEC). In some embodiments, the amount of 3GEC is effective to increase energy expenditure, sympathetic nervous system activity, and/or fat oxidation. Such a composition can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In some embodiments, the composition can improve insulin sensitivity, glucose tolerance, cognitive performance, cognition, mood and/or memory. In some embodiments, the composition can achieve a therapeutic effect selected from the group consisting of blood vessel dilation, reduced blood pressure, increased delivery of blood flow to tissues in the body, improvement of blood circulation, e.g. in brain, stimulation of protein synthesis, increased release of growth factors, enhanced immune function, and combinations thereof. In some embodiments, the composition can treat or prevent dysphagia, e.g.

Abstract: Provided are compositions and methods for treatment of cancer and for adoptive T cell therapy (ACT). The compositions comprise one or more derivatives of tricin 7-O-?-D-glucopyranoside (ANTARTINA®). The compositions comprise one or more pharmaceutically acceptable excipients convenient for delivery of the tricin 7-O-?-D-glucopyranoside derivatives. Tricin 7-O-?-D-glucopyranoside derivatives described herein include acetylated tricin 7-O-?-D-glucopyranoside, as well as glucose, maltose, cellobiose, lactose, xylose, and galactose derivatives. The methods include treatment, or reduction in the risk of suffering from, colorectal cancer and hepatocellular cancer.

Abstract: A composition contains at least one probiotic or enzyme selected from the group consisting of (i) a probiotic having ?-glycosidase activity or a ?-glycosidase, (ii) a probiotic having esterase activity or an esterase, (iii) a probiotic having both ?-glycosidase activity and esterase activity or an enzyme having both ?-glycosidase activity and esterase activity, (iv) a first probiotic having ?-glycosidase activity and a second probiotic having esterase activity, (v) a probiotic having ?-glycosidase activity and an esterase, (vi) a ?-glycosidase and a probiotic having esterase activity and (vii) a ?-glycosidase and an esterase. The at least one probiotic can form one or more of oleuropein aglycone, elenolic acid, hydroxytyrosol acetate or hydroxytyrosol from oleuropein. The composition can comprise oleuropein.

Abstract: The invention pertains to a composition for use in producing white matter, producing myelin and/or reducing brain lesion size in a mammal suffering from or recovering from traumatic brain injury, comprising enterally administering to the subject a composition comprising therapeutically effective amounts of: (i) one or more of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), preferably at least DHA, more preferably DHA and EPA, wherein the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.

Abstract: Low-viscosity, high concentration nucleic acid compositions that can be administered by multiple parenteral routes may allow for less frequent dosing than nucleic acid products currently on the market. In particular, low-viscosity defibrotide formulations for subcutaneous, intramuscular, and intraperitoneal administration are more convenient to the patient and/or are administered outside of the hospital setting. Formulations of the invention may be used for the treatment of numerous conditions including for example, treatment of peripheral arteriopathies, treatment of acute renal insufficiency, treatment of acute myocardial ischemia, and treatment and prevention of sinusoidal obstruction syndrome or VOD.

Abstract: A method is provided of decreasing or increasing the activity of a Pappalysin polypeptide by decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide. Moreover, a method is provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide.

Abstract: The present invention provides a nucleic acid molecule dimer that includes a first nucleic acid molecule having complementarity with at least part of a target nucleic acid molecule, and a second nucleic acid molecule having complementarity with the first nucleic acid molecule, wherein the first nucleic acid molecule has a linear form, the second nucleic acid molecule has a cyclic form, and the first and second nucleic acid molecules at least partially form a double strand.

Abstract: Compositions comprised of oxidized cellulose (OC) in the form of a powder, wherein the carboxyl content of the OC is about 9% to about 18%, by weight, are disclosed. Optionally, the powder is in an aggregated form. Uses of the compositions for preventing tissue adhesion in the presence of bleeding are further disclosed.

Abstract: The present invention discloses a mixture of fucosylated chondroitin sulfate oligosaccharides having an average molecular weight between 2700 Da and 3600 Da, in which 90% of total components has a molecular weight between 1800 Da and 5400 Da. The mixture of fucosylated chondroitin sulfate oligosaccharide of the present invention has very low anti-FIIa factor activity, very low anti-FXa factor activity, very high anti-FXase factor activity, i.e., having a significant activity in selectively inhibiting intrinsic FXase, and a significant antithrombotic activity and no risk of bleeding and hypotension that are proved through animal experiments. The present invention also discloses a method for rapidly producing fucosylated chondroitin sulfate oligosaccharides by using sea cucumber as raw material, and the method includes: intercepting and concentrating crude polysaccharide with a membrane, deacetylation with hydrazine, pyrolysis with nitrous acid, reduction with sodium borohydride, membrane separation, etc.

Abstract: This invention relates to a solid veterinary formulation and a method for its oral administration to an animal, especially cats or dogs, to remove fluid overload in the animal by using a mixture of a water-absorbing polymer and solid fat, optionally having one or more supplemental ingredients. The fluid overload is caused by congestive heart failure or renal disease. The polymer is capable of absorbing at least 10 times its weight in physiological saline. The polymer and other waste materials are excreted in the feces.

Abstract: The present invention relates to a method for producing encapsulated liquid oxygen to maintain blood homeostasis is disclosed. The composition contains a carrier, encapsulated nano-bubbles with one or more gases, preferably liquid oxygen. The methods and compositions may be administered to a patient to deliver liquid oxygen to the patient's blood supply or directly to a tissue in need of liquid oxygen. The methods and compositions are also meant to eliminate carbon dioxide from blood. The compositions may be administered via injection or as a continuous infusion to a patient in an effective amount to increase oxygen concentration in the patient's blood and/or one or more tissues or organs. The encapsulated liquid oxygen may be administered alone or in combination with other treatments as an adjunctive therapy.

Abstract: A method of treating and/or preventing viral infections including common cold, influenza, and coronaviruses with or without symptoms is based on a fact that virus's survival time depends on the temperature and relative humidity, and an assumption that a virus can be killed or its ability to penetrate and replicate copies inside living cells can be weakened, by prolonged exposure to such environment, which can be controlled by an individual. Creating such environment in the upper respiratory and gastrointestinal (GI) tracts and preventing spread of the virus into the lower part of the respiratory tract using continuous and prolonged heat exposure on the virus, prevents development of pneumonia.

Abstract: An iodinated contrast medium (ICM), for use as a medicament for preventing radioactive iodine uptake by the thyroid gland after a nuclear accident. The ICM can advantageously be administered via the sublingual route. The ICM can include a triiodophenyl derivative and several hydrophilic groups.

Abstract: Provided are nanoparticles for the selective death of cancer cells through ferroptosis and a method of preparing the same. More particularly, the nanoparticles are in a form in which a cancer cell-targeting hydrogel and iron particles are bound and aggregated, and are selectively accumulated in cancer cells, and thus exhibit an effective cancer cell killing effect through ferroptosis, and accordingly, are expected to exhibit high therapeutic effects due to less side effects.

Abstract: The present invention provides a method of identifying a target for preparing an inhibitory chimeric antigen receptor (iCAR) or a protective chimeric antigen receptor (pCAR) capable of preventing or attenuating undesired activation of an effector immune cell. Also provided are a list of iCAR targets, as well as vectors and transduced effector immune cells comprising the nucleic acid molecule and methods for treatment of cancer comprising administering the transduced effector immune cells are further provided.

Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.

Abstract: The invention provides improved anti-BCMA CAR T cell compositions for adoptive T cell therapy for relapsed/refractory multiple myeloma.

Abstract: Provided are a genetically engineered T cell and a pharmaceutical composition using the same. The T cell has an endogenous T cell receptor (TCR) that is inactivated or inactive, comprises encoding of an exogenous receptor bindable to a target antigen, and contains an open reading frame regulated by the exogenous receptor. When the exogenous receptor binds to the target antigen, expression of the open reading frame can be initiated. The T cell has a killing effect on tumor cells and has reduced side effects and enhanced safety.

Abstract: Provided herein are BCMA CARs and CAR-T cells, methods of making, and using the same. In some embodiments, particular dosing regimens, redosing regimens, and combination regimens with lymphodepletion are provided, for the treatment and clinical management of multiple myeloma in subjects in need thereof.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to a method for avoidance of blue light damage by using a stem cell composition. The stem cell composition comprises 10% (v/v) to 50% (v/v) of the conditioned medium of Wharton's Jelly mesenchymal stem cells. The conditioned medium of Wharton's Jelly mesenchymal stem cells is prepared by culturing Wharton's Jelly mesenchymal stem cells in a medium containing human basic fibroblast growth factors for 2 to 5 days, and collecting the medium for centrifugation and filtration.

Abstract: The present invention provides a pharmaceutical composition comprising mesenchymal stem cells, a hyaluronan and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for the treatment of the joint disease. The mesenchymal stem cells in the composition are at least one selected from the group consisting of infra-patellar fat pad stromal cells, bone marrow stem cells, Wharton's jelly stem cells and adipose derived stem cells. The concentration of the hyaluronan is in a range from 25% (v/v) to 75% (v/v). The present invention further provides a method for treating a joint disease, comprising a step of administrating a composition containing mesenchymal stem cells, a hyaluronan and a pharmaceutically acceptable carrier to an injured joint tissue of a subject.

Abstract: The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included.

Abstract: The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells.

Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.

Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Abstract: The invention relates to the prognosis and treatment of colon cancer. In particular, the present invention concerns the role of intestinal microbiota in the anticancer immune response elicited by ileal enterocytes succumbing to apoptosis, and provides immunogenic compositions for treating colorectal cancer (CRC), as well as signatures for prognosing CRC evolution.

Abstract: The present invention provides novel methods for treating and preventing colorectal cancer in a subject by administering a composition comprising ?-galactosidase, a bacterial culture capable of producing ?-galactosidase, such as an S. thermophilus culture, or a fraction of the culture comprising ?-galactosidase. A kit useful for such methods is also provided. In addition, the present invention provides a composition for treating or preventing colon cancer.

Abstract: The present disclosure relates to the field of microbial technology, and discloses a probiotic composition and use thereof. The probiotic composition in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631 and Lactobacillus rhamnosus CCFM1044, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering epididymal fat content, lowering fasting blood glucose level, lowering the area under sugar tolerance curve and lowering contents of serum low density lipoprotein and total cholesterol, improving liver antioxidant capacity and lowering serum IL-1? content, etc. The extent of decrease or increase is increased by 9.62% to 769.62% compared with formulations of a single probiotic or a combination of two probiotics. The combination of three probiotics achieves a significant synergistic effect.

Abstract: A main object of the present technology is to provide a composition for muscle mass increase capable of effectively increasing muscle mass with fewer side effects and high safety.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The present disclosure relates to the field of microbial technology, and discloses a composite probiotics and the use thereof. The composite probiotics in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631, Lactobacillus rhamnosus CCFM1044 and Lactobacillus casei CCFM711, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering contents of serum low density lipoprotein, total cholesterol, and liver triglyceride and contents of serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and IFN-?, and increasing contents of liver glutathione and superoxide dismutase, etc. The extent of decrease or increase is increased by 7.91% to 837.31% compared with the formulations of CCFM8630 or CCFM8631 alone or combination of the two probiotics. The combination of the four probiotics can achieve a significant synergistic effect.

Abstract: The present invention relates to new combination therapies of HBV-infected individuals using a Parapoxvirus ovis (PPVO) and at least one further antiviral drug, e.g., nucleoside inhibitors, such as Entecavir. The methods and combination products according to the present invention are safe and suitable for the induction of a functional cure in chronically HBV-infected patients.

Abstract: The present invention provides method for treating a metabolic disorder, dietary intolerance, or malabsorption in a subject that causes an excess of a metabolite or a dietary substance, particularly a carbohydrate such as galactose or fructose, that the subject does not tolerate by administering an effective amount of an adaptively evolved yeast strain to the subject or to food that reduces the excess of the metabolite or dietary substance. Specifically, the invention is directed to methods for treating the metabolic disorder, such as galactosemia or fructosemia, in which an excess of the carbohydrate is present. The invention also provides isolated, adaptively evolved yeast strains that degrades a metabolite or dietary ingredient, such as galactose or fructose, and methods for preparing such isolated, adaptively evolved yeast strains.

Abstract: The present invention provides herbal formulations, methods for their preparation, and methods of treating herpes simplex. The formulations can provide good permeability and bioavailability at the target site.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alpha-herpesvirus infection comprising an Elaeocarpus sylvestris extract or a fraction thereof as an active ingredient, and can effectively prevent, treat or alleviate an alpha-herpesvirus and diseases caused thereby, such as herpes, encephalitis, genital herpes, chicken pox, or herpes zoster.

Abstract: Compositions and methods include a synergistically effective combination of glycerol and Phyllanthus emblica extract for increasing muscle volume in response to an exercise stimulus of the corresponding muscle or muscle region.

Abstract: The present invention provides formulations and methods for formulation administration that support an individual's body during vaccination and adaptive immune response. The individuals who can benefit from these formulations and methods for formulation administration are infants, children and adults. The formulations comprise ingredients that may be administered prior to, concurrent with or subsequent to the vaccination. The formulations and methods for formulation administration of the present invention preferably act by selectively targeting enzymatic reactions, epigenetic expression, and an individual's various metabolic pathways in support of immune system homeostasis, maintaining balance between oxidative stress and methylation, fostering balance between Th1 and Th2 responses, or a combination thereof, during vaccination and adaptive immune responses to improve vaccine response and reduce vaccine side effects.

Abstract: The present disclosure relates to a composition for preventing, treating or remedying female climacteric syndrome symptoms, which contains an extract of Pueraria thomsonii flower or bud. The composition according to the present disclosure shows quick effects for preventing, remedying and/or treating female climacteric syndrome symptoms, particularly facial flushing and/or osteoporosis, and thus can be utilized for the hormone replacement therapy (HRT) used for preventing or remedying climacteric syndrome symptoms.

Abstract: A hybrid herbal and drug composition includes an amount of Chinese herb about 0.01 to 5% by weight of the composition; an amount of animal-based matter about 0.01 to 5% by weight of the composition; an amount of vitamin about 0.01 to 5% by weight of the composition; an amount of mineral about 0.01 to 5% by weight of the composition; an amount of hormone about 0.01 to 5% by weight of the composition; an amount of factory produced product about 0.01 to 5% by weight of the composition; and an amount of the purified water about 70% to 99.94% by weight of the composition.

Abstract: The present invention relates to a pharmaceutical composition comprising: —an extract of Ajuga reptans comprising an amount of phenylpropanoids from 30% to 70% by weight with respect to the weight of the extract, wherein said amount of phenylpropanoids comprises an amount from 10 to 50% of teupolioside with respect to the total phenylpropanoid weight, and —an extract of Epilobium comprising an amount from 20 to 50% by weight of polyphenols with respect to the weight of the extract, wherein said amount of polyphenols comprises up to 3% by weight of oenothein B with respect to the total amount of polyphenols. Also described is the pharmaceutical composition of the invention for use in the treatment of prostatic diseases, in particular the benign prostatic hyperplasia.

Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.